NASDAQ:VIR Vir Biotechnology (VIR) Stock Price, News & Analysis $10.62 +0.04 (+0.38%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$10.54 -0.07 (-0.71%) As of 09/11/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Vir Biotechnology Stock (NASDAQ:VIR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vir Biotechnology alerts:Sign Up Key Stats Today's Range$10.38▼$10.9550-Day Range$8.64▼$11.6352-Week Range$4.75▼$11.94Volume2.08 million shsAverage Volume1.87 million shsMarket Capitalization$1.80 billionP/E RatioN/ADividend YieldN/APrice Target$21.57Consensus RatingModerate Buy Company Overview Vir Biotechnology, Inc. is a clinical-stage immunology company focused on developing therapies for serious infectious diseases and cancer. The company uses technologies involving antibodies, T cells, small interfering RNA and other immune-based approaches to discover and develop treatments designed to harness or enhance the body’s immune response. Vir’s development programs have included therapies for hepatitis B, influenza, human immunodeficiency virus and other infectious diseases, as well as oncology applications. Its most prominent commercial product is sotrovimab, an antibody developed with GlaxoSmithKline for the treatment of COVID-19. Vir continues to advance a pipeline of investigational medicines through internal research and collaborations with pharmaceutical and biotechnology partners. Founded in 2016 and headquartered in San Francisco, California, Vir conducts research and development through a global network of employees, collaborators and clinical sites. The company is led by Chief Executive Officer Marianne De Backer, who joined Vir’s leadership team in 2023.AI Generated. May Contain Errors. Read More Vir Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreVIR MarketRank™: Vir Biotechnology scored higher than 37% of companies evaluated by MarketBeat, and ranked 697th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingVir Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialVir Biotechnology has a consensus price target of $21.57, representing about 103.1% upside from its current price of $10.62.Amount of Analyst CoverageVir Biotechnology has only been the subject of 2 research reports in the past 90 days.Read more about Vir Biotechnology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Vir Biotechnology are expected to decrease in the coming year, from ($1.84) to ($2.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vir Biotechnology is -5.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vir Biotechnology is -5.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVir Biotechnology has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Vir Biotechnology's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.99% of the float of Vir Biotechnology has been sold short.Short Interest Ratio / Days to CoverVir Biotechnology has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.Change versus previous monthShort interest in Vir Biotechnology has recently increased by 8.91%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVir Biotechnology does not currently pay a dividend.Dividend GrowthVir Biotechnology does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment1.24 News SentimentVir Biotechnology has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Vir Biotechnology this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for VIR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows3 people have added Vir Biotechnology to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vir Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders2.90% of the stock of Vir Biotechnology is held by insiders.Percentage Held by Institutions65.32% of the stock of Vir Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vir Biotechnology's insider trading history. Receive VIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VIR Stock News HeadlinesVir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Recommendation of "Moderate Buy" from AnalystsSeptember 10 at 3:44 AM | americanbankingnews.comVir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceAugust 31, 2026 | businesswire.comThis looks like plywood. It's not.AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more electricity than an entire office building. One new chip, which looks more like a piece of plywood than a processor, delivers similar performance on a fraction of the power. Tech investing veteran George Gilder says that efficiency gap could decide who wins the next stage of AI. Gilder has identified three companies positioned around this power breakthrough, calling them the Trillion Dollar Triangle.September 12 at 1:00 AM | Eagle Publishing (Ad)Vir Biotechnology, Inc. (VIR) Stock Price, News, Quote & History - Yahoo FinanceAugust 28, 2026 | finance.yahoo.comVir Biotechnology climbs 9% amid post-earnings uptrendAugust 25, 2026 | seekingalpha.comVir Biotechnology’s Earnings Call Signals Data-Driven MomentumAugust 20, 2026 | theglobeandmail.comVir Biotechnology’s HBV Combo Vaccine Study Reaches Completion, Setting Up Key Pipeline CatalystAugust 19, 2026 | tipranks.comVir Biotechnology (VIR) Q2 2026 Earnings Call TranscriptAugust 12, 2026 | finance.yahoo.comSee More Headlines VIR Stock Analysis - Frequently Asked Questions How have VIR shares performed this year? Vir Biotechnology's stock was trading at $6.03 on January 1st, 2026. Since then, VIR shares have increased by 76.1% and is now trading at $10.62. How were Vir Biotechnology's earnings last quarter? Vir Biotechnology, Inc. (NASDAQ:VIR) posted its quarterly earnings data on Wednesday, August, 5th. The company reported $0.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.33 by $0.14. The company's revenue was up 19582.5% on a year-over-year basis. Read the conference call transcript. When did Vir Biotechnology IPO? Vir Biotechnology (VIR) raised $150 million in an initial public offering (IPO) on Friday, October 11th 2019. The company issued 7,142,858 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays served as the underwriters for the IPO. Who are Vir Biotechnology's major shareholders? Top institutional investors of Vir Biotechnology include BlackRock Inc. (12.26%), ARCH Venture Management LLC (7.50%), ADAR1 Capital Management LLC (1.45%) and California State Teachers Retirement System (0.82%). Insiders that own company stock include Endurance (Cayman) Ltd Svf, Vicki L Sato, Backer Marianne De, George A Scangos, Phillip Pang, Jason O'byrne, Mark Eisner, Ann M Hanly, Verneuil Vanina De, Brent Sabatini, Janet Napolitano and Saira Ramasastry. View institutional ownership trends. How do I buy shares of Vir Biotechnology? Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vir Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vir Biotechnology investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Home Depot (HD), Moderna (MRNA) and Visa (V). Company Calendar Last Earnings8/05/2026Today9/12/2026Morgan Stanley 24th Annual Global Healthcare Conference9/14/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 VIR's financial health is in the Green zone, according to TradeSmith. VIR has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VIR CIK1706431 Webwww.vir.bio Phone415-906-4324FaxN/AEmployees367Year Founded2016Price Target and Rating Average Price Target for Vir Biotechnology$21.57 High Price Target$30.00 Low Price Target$18.00 Potential Upside/Downside+103.1%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$437.99 million Net Margins-638.88% Pretax Margin-82.88% Return on Equity-29.99% Return on Assets-23.62% Debt Debt-to-Equity RatioN/A Current Ratio6.04 Quick Ratio6.04 Sales & Book Value Annual Sales$302.59 million Price / Sales5.94 Cash FlowN/A Price / Cash FlowN/A Book Value$5.50 per share Price / Book1.93Miscellaneous Outstanding Shares169,216,000Free Float164,309,000Market Cap$1.80 billion OptionableOptionable Beta1.63 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:VIR) was last updated on 9/12/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm NOT Buying the SpaceX IPO (And What I'm Buying Instead)Don't buy Nvidia... Not when the AI companies that will define the next decade are selling for pennies. You wo...Decentralized Masters | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredThis 38 Dollar Fund Holds Every Major AI Stock and Pays WeeklyThe biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...Investors Alley | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vir Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VIR Stock Alerts